Janssen
Johnson & Johnson’s arthritis drug shows promising results in Phase III trial
March 16, 2021Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.
Beyond Batten Disease Foundation partners with Actelion on development of combination treatment
March 4, 2021Actelion, Batten disease, Janssen
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …
FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use
March 1, 2021Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines
The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …
Janssen announces positive Phase III results for prostate cancer drug apalutamide
February 10, 2021Research and Development Cancer, Janssen
Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …
Janssen’s esketamine nasal spray gets Europe approval for new indication
February 9, 2021Manufacturing and Production Europe, Janssen
The European Commission (EC) has authorised the expanded use of Janssen’s Spravato (esketamine nasal spray), co-administered with oral antidepressant therapy in …
FDA approves Janssen’s AL amyloidosis drug
January 18, 2021Sales and Marketing FDA, Janssen
The FDA has approved Janssen’s DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone …
EMA receives filing for Janssen’s twice-yearly schizophrenia jab
December 7, 2020Sales and Marketing EMA, Janssen, schizophrenia
The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …
Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia
December 7, 2020Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica
Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
Janssen scoops up rights to Hemera’s gene therapy for retinal geographic atrophy
December 3, 2020Sales and Marketing Hemera Biosciences, Janssen, Retina, geographic atrophy
Janssen is set to acquire the rights to Hemera Biosciences’ intravitreal gene therapy injection HMR59, the company has announced, to …
European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo
December 2, 2020Research and Development, Sales and Marketing Europe, Janssen, Tremfya
The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …
Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn
November 17, 2020Manufacturing and Production, Research and Development BARDA, COVID-19, J&J, JJ, Janssen, Vaccine
Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …
J&J launches second global COVID-19 vaccine trial, evaluating two-dose regimen
November 16, 2020Research and Development, Sales and Marketing COVID-19, J&J, JJ, Janssen, Vaccine
Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …
CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis
October 19, 2020Sales and Marketing CHMP, EMA, Janssen, Tremfya
Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …
European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine
October 9, 2020Medical Communications AZ, AstraZeneca, Janssen
The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s …
Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia
September 7, 2020Sales and Marketing Europe, Janssen, imbruvica, pharma
The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
